ArticleBiotechnology journal2026
Engineering Yarrowia Lipolytica for De Novo Biosynthesis of Abscisic Acid.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Abscisic acid (ABA) is a sesquiterpenoid plant hormone widely used in agriculture and the food industry. In Yarrowia lipolytica, ABA production relies on complex heterologous enzymatic pathways that have not been systematically engineered, which severely limits biosynthetic efficiency. Here, we establish de novo ABA biosynthesis in Y. lipolytica. We optimized carbon flux by up- and down-regulating key genes, and rationally engineered rate-limiting cytochrome P450 monooxygenases BcABA2 to improve pathway efficiency. Electron transfer was engineered by incorporating an NADPH regeneration module to enhance BcABA2 catalysis. Peroxisomal compartmentalization of the entire ABA pathway, followed by complementation of the defective tag to obtain a complete strain, increased ABA titer to 330.69 mg/L. The engineered strain was scaled up in a 5 L bioreactor, achieving an ABA titer of 2554.36 mg/L after 168 h, which is the highest titer reported to date for microbial fermentation. This work provides feasible enzyme and metabolic engineering strategies for microbial cell factory production of ABA and other terpenoids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.